Nervous Disorder TRIZ Cases

Water-soluble polymers form stable complexes with cholinergic alkaloids, ensuring uniform distribution and high bioavailability while preventing segregation.

Oral pridopidine activates sigma-1 receptors to upregulate neurotrophic factors, slowing functional capacity decline beyond symptomatic relief.

Oct4 combined with Bmi1 reprograms somatic cells into pluripotent stem cells, reducing genetic complexity while maintaining differentiation potential.

Furoxan compounds inhibit caspase-6 to mitigate neurodegenerative disease progression.

Blood-based biomarkers replace invasive procedures to improve diagnostic accuracy and treatment monitoring.

Osmotin protects neurons from ethanol-induced apoptosis by inhibiting cytochrome-c release and modulating caspase expression.

Covalent attachment of a polymer to the N-terminal alpha-amino group of recombinant human nerve growth factor extends its in vivo half-life.

Mitostatic compounds modulate mitochondrial dynamics to restore cellular health.

A non-covalent dimer cation scavenges reactive oxygen species to reduce oxidative stress in liver cells.

ALCAT1 inhibitors block pathological cardiolipin remodeling to reduce oxidative stress in metabolic diseases.

SPINK2 mutant peptides inhibit KLK protease activity through disulfide bond stabilization.

Anti-Siglec-7 antibodies bind cell surface proteins to reduce expression, inhibiting ligand interactions and modulating activities for therapeutic treatment.

Oral esketamine dosage resolves administration complexity and genotoxicity risk.

Anti-IFNAR1 monoclonal antibodies target SD2 and SD3 domains to block interferon signaling, addressing insufficient targeting in current autoimmune treatments.

KEAP1 inhibitors activate NRF2 to restore lysosomal acidity, resolving autophagosome accumulation in neurodegenerative diseases.

A synergistic nutritional composition of magnesium L-threonate and homotaurine enhances synaptic density and brain plasticity.

Targeted AAV gene delivery enhances local CNTF receptor signaling in muscle, avoiding systemic side effects while slowing ALS progression.

Chrexanthomycin A targets multiple pathological pathways by binding G-quadruplexes, scavenging ROS, and inhibiting tau aggregation to halt disease progression.

Animal-derived enzymes convert toxic acetaldehyde into acetate, resolving liver toxicity risks from pain relievers.

High-dose pooled immunoglobulin G slows dementia progression in ApoE4 carriers and moderate cases, addressing the failure of current symptomatic therapies.

A decanoic acid to octanoic acid ratio composition inhibits AMPA receptors.

Segmenting racemic mixtures into pure R(-) enantiomers eliminates neurotoxicity and hyperthermia risks while preserving therapeutic efficacy.

Deuterium oxide alters circadian rhythms via kinetic isotope effects, avoiding benzodiazepine sedation.

Genetically engineered neural progenitor cells enhance sonic hedgehog signaling to promote neuronal differentiation.

Targeting MCJ polypeptide expression with specific siRNA sequences regulates mitochondrial metabolism and cytotoxic T cell function to treat metabolic diseases.

Periodic AdDNJ administration balances enzyme enhancement with substrate turnover, reducing amyloid-beta and tau pathology.

Peptides blocking PTEN nuclear translocation reduce infarct areas and improve motor recovery in stroke models.

Bifunctional compounds link cereblon-binding moieties to targeted protein ligands to induce selective degradation.

Extracted Pirin polypeptide regulates NF-kB pathways to reduce inflammation while maintaining intestinal barrier integrity against tissue damage.

A monoclonal antibody binds the Nav1.7 E3 extracellular region to selectively inhibit channel activity.

Amide derivatives bind sigma-1 and mu opioid receptors to provide multimodal analgesia while reducing side effects.

APRIL protein binds astrocytes and chondroitin sulfate proteoglycans to inhibit anti-regenerative processes, addressing relapses in multiple sclerosis.

D-amino acid substitution in TVALA pentapeptide extends half-life, addressing thymopentin metabolic instability for ALS treatment.

Pre-form nerve fascicles using glial feeder cells to resolve engraftment reliability issues in spinal cord repair.

A modified biphenyldiol compound accelerates brain penetration to reduce onset time for seizure control compared to traditional dipropofol.

Administering a PSD-95 inhibitor before reperfusion reduces hemorrhagic risks and infarction size, extending the therapeutic time window beyond standard limits.

Modified oligonucleotides target C9ORF72 antisense transcripts to treat neurodegenerative diseases driven by hexanucleotide repeat expansions.

Nitroxide antioxidants modulate APEX1 expression to reduce cancer and autoimmune disease risks.

A classification algorithm predicts antidepressant treatment response using specific genetic polymorphisms and clinical features.

D1/D5 receptor antagonists inhibit dopamine access to treat stuttering without inducing the condition.

A topical lotion formulation combines multiple analgesic agents into a single base cream for enhanced skin penetration.

Androstane triol compounds inhibit NF-kB activity to reduce inflammation without activating glucocorticoid receptors.

Cannabigerol proline cocrystals resolve polymorphic instability and degradation during manufacturing by raising the melting point above 150°C.

A betulin and gamma-cyclodextrin composition enhances cognitive functions.

Inhibit LONP1 protease to deplete deleterious mitochondrial genomes, resolving the accumulation bottleneck that drives aging and inherited disease.

Combining azeliragon with radiation therapy extends median survival to 18 months against the 14.6-month standard.